Is Semax legal in the UK?

It is supplied as a material for laboratory research. It is not a licensed medicine here and cannot be prescribed or dispensed.

Does Russian registration mean it is proven?

It means one regulator assessed a submission against its own standards and granted an authorisation. Standards differ between agencies and have changed over three decades.

Could Semax be approved in the UK?

Only through an application to and assessment by the MHRA. No such process has taken place.

Semax (ACTH Fragment Peptide)

Semax Regulatory Status: Registered Where, and Why It Matters

JMWritten & reviewed by Jack Muncaster · Founder, UK PeptidesLast reviewed 2026-08-234 cited sources

Semax has been registered as a prescription medicine in the Russian Federation since the 1990s. It holds no marketing authorisation from the MHRA, EMA or FDA, has not been through Western regulatory review, and is supplied in the UK for laboratory research only.

Key facts

Registered in: Russian Federation
Registered since: 1990s
MHRA status: Not authorised
EMA status: Not authorised
FDA status: Not approved
UK supply basis: Laboratory research only
Transferable?: No — authorisations are jurisdictional

What a national registration is

A marketing authorisation is a decision by one regulator, about one product, in one jurisdiction, for defined indications, on the evidence submitted to it. It reflects that regulator's evidentiary standards and its assessment of benefit and risk for its own population. It is not a statement about a compound in the abstract, and it does not travel.

Why registration elsewhere does not change UK status

The MHRA assesses products submitted to it. A compound registered in Russia, or anywhere else, has no UK status until a UK application is made and assessed. Semax has not been through that process. Its position in the UK is therefore identical to any other unlicensed compound: it is not a medicine here, cannot be prescribed or dispensed, and is supplied for laboratory research.

Research material referenced

Semax 10mg — third-party HPLC tested

View — £24.99

Why the difference in standards matters

Regulators differ in what evidence they require and how they weigh it, and those requirements have changed considerably over three decades. A registration granted in the 1990s on the evidence available then would not necessarily survive assessment against current standards for trial design, pre-registration and reporting. This is true generally and is not a claim specific to any one agency.

The line this site keeps

Reporting that a national regulator registered a compound for named indications is a fact about a decision. Stating or implying that the compound treats those conditions is a therapeutic claim, and under the UK framework a therapeutic claim about material supplied for research is what converts it into an unlicensed medicine. The MHRA opened investigations into UK retailers making exactly that kind of claim in April 2026. This distinction is the reason these pages describe registrations rather than repeating indications as if they were established outcomes.

What would change the position

A UK marketing authorisation, following an application and assessment by the MHRA. Nothing else does — not registration in another country, not published literature, not length of use elsewhere.

Extended research context

The Semax (ACTH Fragment Peptide) deep dive

Deep dive: what the Pro-Gly-Pro extension actually accomplishes

Semax is built from a four-residue fragment of ACTH with Pro-Gly-Pro appended, and that appendix does two separate jobs at once. Proline is the only proteinogenic amino acid whose side chain bonds back to its own backbone nitrogen, forming a ring that removes the amide hydrogen and locks rotation. Proteolytic enzymes generally need an extended, rotatable backbone at their active site, so bonds near proline are poor substrates for most of them — which is why proline-rich motifs recur throughout stabilised peptide design. The second job is subtractive: Pro-Gly-Pro occupies the positions where ACTH carries Arg-Trp-Gly, and those are the residues contributing to the parent hormone's adrenal-stimulating activity. One substitution therefore buys protease resistance and removes an unwanted pharmacology, which is unusually economical design.

Deep dive: the naming point worth getting right

Semax is near-universally described as an ACTH(4-10) analogue, and peer-reviewed paper titles use that phrase. Structurally it is not quite that. ACTH residues 4 to 10 are Met-Glu-His-Phe-Arg-Trp-Gly; Semax is Met-Glu-His-Phe-Pro-Gly-Pro. The first four residues match and the last three are wholly different — replacement rather than modification. PubChem, indexing by structure rather than design lineage, records it as ACTH(4-7) plus Pro-Gly-Pro. Neither name is wrong, but the loose one obscures the fact that the substituted segment is precisely the functionally consequential part.

Deep dive: reading an unevenly distributed evidence base

Semax's roughly 231 indexed records split along an unusual line. Mechanistic work — BDNF and trkB expression in rat hippocampus, transcriptomics in focal cerebral ischaemia, neurotrophin dynamics across brain regions — appears in international journals in English and can be assessed directly. Clinical work is concentrated in Russian-language publications, principally the Korsakov Journal of Neurology and Psychiatry, indexed by translated title and often without accessible English full text, much of it predating current standards for pre-registration and reporting. The honest position is that this is evidence which is difficult to verify independently, which is a different thing from evidence that is absent, and a different thing again from evidence that is established.

Research applications

▸Neurotrophin expression research (BDNF, NGF, TrkB, TrkA)
▸Neuroprotection and cerebral ischaemia models
▸Study of proline-stabilised peptide design
▸Comparative work on ACTH fragments without steroidogenic activity
▸Transcriptomic profiling in rodent brain models

Handling checklist

✓Store lyophilised material cold, dry and protected from light
✓Expect methionine oxidation as the degradation route (+16 Da; only one Met, so not +32)
✓No reducing agent needed — the sequence contains no cysteine
✓Introduce diluent gently against the vial wall; swirl rather than shake
✓Aliquot to avoid repeated freeze-thaw cycles
✓Check whether a certificate reports net peptide content or gross salt weight

Common research-handling mistakes

Learnt from thousands of researcher orders across our UK labs.

✗ Describing Semax as ACTH(4-10) without qualification

Fix: It shares only residues 4-7; Pro-Gly-Pro replaces Arg-Trp-Gly, and that replacement is the design's whole point.

✗ Treating Russian registration as equivalent to MHRA approval

Fix: Authorisations are jurisdictional and do not transfer. Semax has never been assessed by the MHRA, EMA or FDA.

✗ Reading a BDNF expression change as a demonstrated outcome

Fix: The studies measured gene and protein expression in rats. Expression is upstream of function and upstream again of any clinical claim.

✗ Assuming a named receptor exists

Fix: No primary receptor has been definitively established; the literature characterises downstream effects more confidently than the initiating event.

✗ Expecting ACTH-like adrenal effects

Fix: Semax does not stimulate adrenal steroidogenesis — the responsible residues were substituted out.

Continue researching

Peer-reviewed guides, comparators and matched reference materials.

Frequently asked questions

Is Semax legal in the UK?: It is supplied as a material for laboratory research. It is not a licensed medicine here and cannot be prescribed or dispensed.
Does Russian registration mean it is proven?: It means one regulator assessed a submission against its own standards and granted an authorisation. Standards differ between agencies and have changed over three decades.
Could Semax be approved in the UK?: Only through an application to and assessment by the MHRA. No such process has taken place.

Primary sources & clinical trials

Peer-reviewed research and registered trials from PubMed, ClinicalTrials.gov, PubChem, FDA and NIH. All links open in a new tab and point to the primary source, so every claim can be verified at origin.

Written and reviewed by

Jack Muncaster · Founder, UK Peptides

Jack founded UK Peptides in Manchester after repeatedly receiving research compounds with missing or recycled paperwork. He is responsible for supplier selection, batch release decisions and the content published in this research library. Every article here is sourced to primary literature and every product page to a signed third-party certificate.

How we write and check this content Report a factual error in this article

More Semax (ACTH Fragment Peptide) articles

Popular across the research hub

One flagship guide from every other research category — keep exploring.

← Back to Forum